Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~All Participants:~* Body Mass Index ≥18 to ≤40 kg/m\^2~* Females of childbearing potential must either be sexually inactive (abstinent) for 14 days prior to dosing and throughout the study or are using an acceptable birth control method~* Females of non-childbearing potential must have undergone a sterilization procedure at least 6 months prior to dosing or are postmenopausal with amenorrhea for at least 1 year prior to dosing and have follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status~* Male subjects must agree not to donate sperm from dosing until 90 days after dosing~Participants with Moderate or Severe Renal Insufficiency:~* Health of participant is stable based on medical history, laboratory tests and other assessments~* Clinical diagnosis of impaired stable renal function, and a creatinine clearance (CLcr) of \<30 mL/min and not on hemodialysis for severe renal insufficiency participants, or 30 to \<50 mL/min for moderate renal insufficiency participants~* No clinically significant change in renal status for at least 1 month prior to dosing, and is not currently or has not previously been on hemodialysis~Healthy Control Participants:~* Participant is medically healthy based on laboratory tests and other assessments~* Age of the individual healthy participants in Part 1 of the study is aimed to be within the range of the mean age ± approximately 15 years of all participants with renal impairment in Part 1 of the study combined; this approach will also be applied with respect to age of participants in Part 2 of the study~* CLcr ≥80 mL/min~Exclusion Criteria:~All Participants:~* Mentally or legally incapacitated, significant emotional problems at screening or expected during the conduct of the study or history of a clinically significant psychiatric disorder over the last 5 years~* History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, or neurological disease whose current condition is considered unstable~* History or presence of alcoholism and drug abuse within the past 6 months~* History or presence of hypersensitivity or idiosyncratic reaction to the study medication or related compounds~* Female participants who are pregnant or lactating~* Positive results for the urine or saliva drug screen, or for the urine or breath alcohol screen~* Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)~* Regular user of any medication (including over the counter) that would significantly alter renal function (e.g., cimetidine)~* Donation of blood or significant blood loss within 56 days prior to dosing, or donation of plasma within 7 days prior to dosing~* Participation in another clinical trial within 28 days prior to dosing~* No participant may be enrolled more than once within Part 1. Subjects who participate in Part 1 of study may be enrolled in Part 2, but participants within Part 2 are not to be enrolled more than once in Part 2~Healthy Control Participants:~* Participant has had a renal transplant or has had nephrectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Severe Renal Insufficiency Participants: Part 1 (Type: EXPERIMENTAL): Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
- Moderate Renal Insufficiency Participants: Part 1 (Type: EXPERIMENTAL): Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
- Healthy Control Participants: Part 1 (Type: EXPERIMENTAL): Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
- Severe Renal Insufficiency Participants: Part 2 (Type: EXPERIMENTAL): Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
- Moderate Renal Insufficiency Participants: Part 2 (Type: EXPERIMENTAL): Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
- Healthy Control Participants: Part 2 (Type: EXPERIMENTAL): Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.

Based on this trial design, predict the completion outcome and termination type (if applicable).